Genzyme Corp.'s board rejected Sanofi-Aventis SA's $69-per-share offer yet again, a move that came as no surprise to anyone following the ongoing saga. But it was a late Thursday SEC filing by the Cambridge, Mass.-based biotech that really got tongues wagging, particularly the disclosure of a meeting between the top execs during which Sanofi's CEO reportedly proposed a $69 to $80 per share price range to start negotiations. (BioWorld Today)